Skip to main content

AlphaLISA Human PD-1/PD-L1 Binding Kit, 100 Assay Points

The AlphaLISA® human PD-1/PD-L1 binding kit is designed for the detection of binding activity between human PD-1 and PD-L1, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Part Number: AL356HV
Unit Size:
Part Number: AL356C
Unit Size:
Part Number: AL356F
Unit Size:
  • This kit is designed for the detection of binding activity between PD-1 and PD-L1 using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of therapetics by using competitive binding.

    Features:

    • No-wash steps, no separation steps
    • Ease-of-use: few addition steps, fast assay development
    • Broad range of affinities: detect strong or weak interactions, from pM to mM affinity
    • Distance: measure very large protein or antibody complexes – spanning up to 200 nm or more
    • High avidity: multiple binding sites on each bead enables use of nanomolar concentrations of antibodies or proteins, as well as use of low affinity binders

    AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated PD-1 binds to the Streptavidin-coated Alpha Donor beads, while His tagged PD-L1 is captured by Anti-His AlphaLISA Acceptor beads. When PD-L1 binding to PD-1 happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

    Programmed death ligand 1 (PD-L1), also known as "cluster of differentiation 274" (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and is expressed in tumor cells. PD-L1 binds to its receptor, PD-1, found on activated T cells, B cells, and myeloid cells, to modulate activation or inhibition. By binding to PD-1, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression and thus contribute to cancer growth. Monoclonal antibodies targeting PD-1 and PD-L1 are being developed as a means to boost the immune system for the treatment of non-small-cell lung cancer, melanoma, bladder, renal, and triple-negative breast cancers.

  • Application
    Protein-protein interactions
    Assay Points
    100
    Assay Target Class
    Protein
    Automation Compatible
    Yes
    Brand
    AlphaLISA
    Detection Method
    Alpha
    Experimental Type
    In vitro
    Format
    Microplates
    Therapeutic Area
    Immuno-oncology

Resources

1-2 of 2 Resources
Flyer
Reagent solutions for autoimmunity research.
alphalisa, alpha, htrf, surefire, autoimmunity, flyer
Application Note Icon Image
Application Note
Screening for Inhibitors of PD-1 and PD-L1 Binding with AlphaLISA Technology
pd-1, pd-l1, binding, interaction, binding assay, pdl-1, pd1